Skip to main content
PepStack
Wiki · Profile

ACE-031

ACVR2B-Fc · Bimagrumab precursor

IGF Axis & MusclePhase II
From$18.00/mgCompare prices

ACE-031, also known as Ramatercept, is a dimeric fusion protein that consists of a fragment of the human activin receptor IIB (ACVR2B) linked to the Fc region of human IgG1. Researchers primarily study ACE-031 for its potential to inhibit myostatin, a protein that negatively regulates muscle growth, making it a candidate for addressing muscle-wasting conditions such as Duchenne muscular dystrophy. Key findings from clinical studies suggest that while ACE-031 was generally well-tolerated and associated with increases in lean body mass and muscle volume, safety concerns led to the discontinuation of some trials. Current research status indicates that ACE-031 remains a focus of investigation, particularly in the context of its effects on muscle growth and metabolism, although it is not yet approved for clinical use and is often found in black market products.

Chemical Profile

Chemical Profile

Half-Life

INIntranasal

Not applicable

POOral

Not applicable

The pharmacokinetic profile suggests a long half-life suitable for less frequent dosing, but specific data is limited.

Mechanism

Mechanism of Action

ACE-031 (Ramatercept) is a dimeric fusion protein that acts as a decoy receptor for myostatin and other ligands of the activin receptor IIB (ACVR2B), thereby inhibiting their signaling pathways, which are primarily involved in the negative regulation of skeletal muscle growth. By binding to myostatin, ACE-031 disrupts the TGF-β signaling pathway, leading to enhanced muscle stem cell proliferation and differentiation, increased protein accretion in muscle fibers, and overall promotion of muscle mass. The precise mechanisms of action and downstream effects of ACE-031 on various biological processes are not fully understood and require further investigation.

Research

16 Research Publications

574

Total Citations

4

Human/RCT

3.3

Avg. Influence

2025

Latest

Sort
Filter
#01

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

HumanInfluence5.0
223
Researchers observed trends in maintenance of walking distance and increases in lean body mass and bone mineral density in boys with Duchenne muscular dystrophy receiving ACE-031, although the study was discontinued due to safety concerns.
0.02-3 mg/kgsubcutaneous(human)3 mg/kg(human)29 days
PubMed
#02

A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.

HumanInfluence4.0
173
Researchers observed that a single dose of ACE-031 in healthy postmenopausal women resulted in significant increases in total body lean mass and thigh muscle volume, indicating its potential for promoting muscle growth.
0.02-3 mg/kgsubcutaneous(human)3 mg/kg(human)29 days
PubMed
#03

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

AnimalInfluence3.0
141
Researchers observed that administration of ACE-031 in mice increased muscle mass independent of fiber type, suggesting its potential as a therapeutic agent for musculoskeletal diseases.
0.02-3 mg/kgsubcutaneous(human)3 mg/kg(human)29 days
PubMed
#04

Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.

AnimalInfluence1.0
36
Researchers observed that numerous compounds, including ACE-031, may enhance skeletal muscle function and mitochondrial biogenesis, raising concerns for potential misuse in sports and the need for effective doping control measures.
0.02-3 mg/kgsubcutaneous(human)3 mg/kg(human)29 days
PubMed
#05

Gel Electrophoretic Detection of Black Market ACE-031.

Reichel Christian, et al. · Drug testing and analysis · 2025

Animal
1
Researchers observed that black market ACE-031 products contained full-length human activin receptor IIB rather than the intended fusion protein, highlighting challenges in detection and potential risks of unregulated substances.

Key findings

  1. 01Of 14 tested black market products, 12 contained a protein that was not ACE-031 but rather the full-length human activin receptor IIB.
  2. 02The study developed a detection method that successfully identified these products in rat serum for up to 48 hours after administration.
  3. 03The presence of additional proteins in the black market products indicates potential risks associated with their use.
0.02-3 mg/kgsubcutaneous(human)3 mg/kg(human)29 days
PubMed
#06

[Anti-myostatin antibody therapy for myopathies].

Animal
Researchers observed that various approaches, including the myostatin decoy receptor ACE-031, are being explored for anti-myostatin therapy in muscular dystrophies, necessitating further evaluation for safety and efficacy.
0.02-3 mg/kgsubcutaneous(human)3 mg/kg(human)29 days
PubMed
#07

[Myostatin blockade therapy for muscular atrophy].

Animal
Researchers observed that myostatin inhibition, including the use of ACE-031, could be effective for various muscle-wasting conditions and may have broader applications in metabolic diseases beyond muscular dystrophy.
0.02-3 mg/kgsubcutaneous(human)3 mg/kg(human)29 days
PubMed
#08

Combined rapamycin and mesenchymal stem/stromal cells derived from induced pluripotent stem cells-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.

Gao Pan, et al. · JBMR plus · 2025

Animal
Researchers studied a genetic condition called fibrodysplasia ossificans progressiva (FOP), which causes abnormal bone growth. They found that combining a specific protein treatment with stem cells from induced pluripotent stem cells significantly reduced this abnormal bone formation in a mouse model.

Key findings

  1. 01Researchers observed that the combination of rapamycin and stem cells effectively reduced heterotopic ossification in mice with FOP.
  2. 02The study highlighted the role of the ACVR2B-Fc fusion protein in managing the effects of the disease.
  3. 03Findings suggest a potential new approach for addressing abnormal bone growth associated with FOP.
PubMed
#09

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.

Gao Pan, et al. · Stem cell research & therapy · 2024

In Vitro
Researchers studied a rare genetic disease called fibrodysplasia ossificans progressiva (FOP), which causes abnormal bone growth. They found that using a specific type of stem cell, combined with a candidate drug, reduced this abnormal bone formation in a mouse model, suggesting a potential new approach for treatment.

Key findings

  1. 01Researchers observed that stem cells expressing ACVR2B-Fc reduced abnormal bone growth in a mouse model of FOP.
  2. 02The study found that ACVR2B-Fc secreted by these stem cells decreased signaling pathways that lead to bone formation.
  3. 03Local injections of these modified stem cells improved movement performance in the mice.
PubMed
#10

Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.

Zhong Xiaoling, et al. · Journal of cachexia, sarcopenia and muscle · 2022

Human
Researchers studied the effects of pancreatic cancer cachexia, a severe muscle-wasting condition, in both mice and humans, focusing on how it differs between sexes. They found that male mice experienced more severe muscle loss compared to females, and this pattern was mirrored in human patients, where men showed greater muscle wasting than women. The hormone Activin was identified as a key factor driving this muscle loss, highlighting the need for sex-specific approaches in treatment development.

Key findings

  1. 01Male mice with pancreatic cancer exhibited earlier and more severe muscle loss compared to female mice.
  2. 02In human patients, men experienced greater and faster muscle wasting than women during treatment for pancreatic cancer.
  3. 03The hormone Activin plays a significant role in muscle loss, particularly in males, suggesting that sex differences are crucial for understanding and treating cachexia.
PubMed
Safety

Safety & Handling

Research Gaps

No long-term safety and efficacy data from human trials of ACE-031 are available, particularly regarding its effects on muscle growth and metabolism over extended periods. Additionally, the precise mechanisms by which ACE-031 influences muscle mass and its potential interactions with other metabolic pathways remain unclear.

Solubility

Soluble in water and saline solutions, limited solubility in organic solvents.

Storage & Handling

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Safety information is derived from published research and may not reflect all known risks. This is not medical advice.

Legal Status

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not scheduled by the DEA.

🇦🇺AU

Not listed in the Australian Register of Therapeutic Goods (ARTG).

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Community Insights

Community Insights

Publications per Year

7 total
1
10
2
11
1
13
1
16
1
17
1
25
Pricing

Price Comparison

  • BESTUmbrella LabsUS
    5mg
    $89.99
    Price/mg
    $18.00/mg
    View
  • Geo PeptidesUS
    1mg
    $29.99
    Price/mg
    $29.99/mg
    View
  • Umbrella LabsUS
    2.5mg
    $99.99
    Price/mg
    $40.00/mg
    View
  • BPC-157 PeptideUS
    1mg
    $56.99
    Price/mg
    $56.99/mg
    View
  • Peptides.netUK
    1mg
    $63.50
    Price/mg
    $63.50/mg
    View

Top 5 of 15 offers from 13 vendors. Prices updated daily.

See all ACE-031 prices
Mechanism

Tools

Reconstitution Calculator

Calculate reconstitution volumes for ACE-031

Serum Level Visualizer

Visualize ACE-031 serum levels over time

Mechanism

Related Peptides

MGFPEG-MGFFollistatin 344IGF-1 DESIGF-1 LR3

Track ACE-031 in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play
Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer